Posts by tag
metastatic cancer
Sixteen Years Clear, Then it Came Back: A Husband’s Reckoning with Cancer, Faith, and the Ordinary Courage of Carrying On
For sixteen years, cancer became something we spoke about in the past tense. My wife, Lynn, had survived a rare smooth-muscle cancer (leiomyosarcoma) after two operations in 2009. Year after year the scans came back clear. Gradually, we stopped living…
Could GLP-1 Drugs Slow Cancer Spread? New Study Offers Encouraging Clues
Treatment with GLP-1 receptor agonists (GLP-1RAs) was associated with a significantly lower risk of progression to metastatic disease in non–small cell lung cancer (NSCLC), breast cancer, colorectal cancer (CRC), and hepatocellular carcinoma (HCC). The study, presented at the 2026 American…
Rewriting RAS: A New Targeted Option on the Horizon for Pancreatic Cancer
Metastatic pancreatic cancer remains one of the most treatment-refractory solid tumours in oncology. Despite multiple incremental refinements over the past decade, first-line therapy continues to rely on cytotoxic chemotherapy, most commonly FOLFIRINOX or gemcitabine plus nab-paclitaxel, with limited change in…
“Between the Checkpoints of Life, Take the Immunobuddies with You” —Professor Ricky Dylan Frazer
The conversation starts with a small detail that quickly becomes memorable. There is no coffee. On a podcast built around conversations over coffee, Professor Ricky Dylan Frazer, Consultant Medical Oncologist at Velindre Cancer Centre, Deputy CEO of the Immuno-Oncology Clinical…
CancerWorld #115 (May 2026)
In oncology, progress is measured in survival rates, response curves, and treatment gains. But those numbers rest on a quieter assumption: that health systems can deliver what science makes possible. When they cannot, progress becomes uneven—not in discovery, but in…
The Day Immunotherapy Went Off-Patent
In oncology, some milestones arrive with applause. Others arrive quietly. This year, one of the most important cancer drugs of the modern era begins to lose its monopoly. Nivolumab, one of the first PD-1 inhibitors to reach patients, is set…
Rethinking Immunotherapy for Pancreatic Cancer: A Universal Approach
Chimeric antigen receptor natural killer T (CAR-NKT) cell therapy, a novel form of immunotherapy, is emerging as a promising ‘off-the-shelf’ treatment for patients with pancreatic cancer. In a study published in PNAS, November 21, 2025, U.S. investigators report that CAR-NKT cells…
Aerobic activity to outcompete metastasis
Aerobic exercise can reduce the risk of developing metastatic cancer by 73%. Using both human epidemiological data and in vivo mouse models of melanoma metastasis, Israeli investigators report in Cancer Research (November 15) that high-intensity aerobic exercise increases glucose consumption…
ESMO provides first recommendations on use of next-generation sequencing in metastatic cancer
Patients with metastatic non-squamous non-small-cell lung cancer (NSCLC), prostate cancers, ovarian cancers and cholangiocarcinoma should be offered next-generation sequencing (NGS) for profiling tumour samples, concludes an expert panel from the European Society for Medical Oncology (ESMO) in their review (Mosele…